| Dr Rebecca L Maki, MD | |
|
1200 56th St Sw, Wyoming, MI 49509-9704 | |
| (616) 243-5707 | |
| (616) 243-1170 |
| Full Name | Dr Rebecca L Maki |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1200 56th St Sw, Wyoming, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255300950 | NPI | - | NPPES |
| 4735871 | Medicaid | MI | |
| 11282599 | Other | MI | CAQH |
| 4735862 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 4301072290 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rebecca L Maki, MD 8485 Algoma Ave Ne, Rockford, MI 49341-9102 Ph: (616) 863-6220 | Dr Rebecca L Maki, MD 1200 56th St Sw, Wyoming, MI 49509-9704 Ph: (616) 243-5707 |
News Archive
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today an agreement to enter into a strategic partnership with Rock-One International Holdings Ltd., a holding company specializing in investment activities, including in the high tech and biomedical industries.
Incyte Corporation today announced that further analyses from the global, pivotal Phase III clinical program of Jakafi (ruxolitinib or INC424) are being presented at the 2011 American Society of Hematology (ASH) Annual Meeting.
TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors today announced that the Company has agreed to be acquired by sanofi-aventis. Under the agreement, the ultimate purchase price will depend on the achievement of certain future milestones events and will total $560M if such milestones are fully realized. The closing of the transaction is expected to occur in the 3rd quarter of 2010.
Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
Tobacco dependence is very common in patients hospitalized with substance use disorders (SUDs) – but most don't receive recommended treatment for tobacco dependence while in the hospital, reports a study in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine
› Verified 9 days ago
Robert Bulten, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4340 Burlingame Ave Sw, Wyoming, MI 49509 Phone: 616-475-7922 Fax: 616-475-7926 | |
Dr. Janet F Johns, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1200 56th St Sw, Wyoming, MI 49509 Phone: 616-514-3803 Fax: 616-243-1170 | |
Dr. Charles G. Lawrence, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1200 56th St Sw, Wyoming, MI 49509 Phone: 616-243-5707 Fax: 616-243-1170 | |
Tiffany Allyn Letts, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2215 44th St Sw, Wyoming, MI 49519 Phone: 616-252-8300 Fax: 616-252-8461 | |
Dr. Jamie D. Bosch, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1200 56th St Sw, Wyoming, MI 49509 Phone: 616-243-5707 Fax: 616-243-1170 | |
Dr. Andrew Dillon Smith, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 2215 44th St Sw, Wyoming, MI 49519 Phone: 616-252-8300 |